Abstract
In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 292-297 |
| Number of pages | 6 |
| Journal | Pharmacogenomics Journal |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2005 |
Fingerprint
Keywords
- β and β adrenergic receptor variants
- Diabetes mellitus
- Hypertriglyceridemia
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine
- Genetics
Cite this
β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene. / Iaccarino, G.; Trimarco, V.; Lanni, F.; Cipolletta, E.; Izzo, R.; Arcucci, O.; De Luca, N.; Di Renzo, G.
In: Pharmacogenomics Journal, Vol. 5, No. 5, 2005, p. 292-297.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene
AU - Iaccarino, G.
AU - Trimarco, V.
AU - Lanni, F.
AU - Cipolletta, E.
AU - Izzo, R.
AU - Arcucci, O.
AU - De Luca, N.
AU - Di Renzo, G.
PY - 2005
Y1 - 2005
N2 - In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.
AB - In this study, the effects of polymorphisms of the β2 and β3 adrenergic receptor genes on the occurrence of dyslipidemia and diabetes mellitus in hypertensive patients treated with β-blockers (atenolol or metoprolol) were evaluated. Patients who gave written informed consent were asked to return for blood sampling for estimation of serum glucose, total cholesterol, HDL, triglycerides and for genotype determination. Genotyping analysis was performed by PCR-RFLP assay. In patients bearing β2AR Glu27 or the β3AR Arg64 variant there was a larger occurrence of hypertriglyceridemia, alone or in combination with elevated cholesterol levels. Furthermore, the β2AR Glu27 variant significantly associates with hypetriglyceridemia in a cumulative fashion. The risk to develop this side effect after β-blockade was four-fold higher in patients homozygous for the β2AR Glu27 variant as compared to β2AR27Gln allele. This result allows the identification of patients at high risk to develop metabolic complications to chronic β-blockade treatment.
KW - β and β adrenergic receptor variants
KW - Diabetes mellitus
KW - Hypertriglyceridemia
UR - http://www.scopus.com/inward/record.url?scp=27144503123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144503123&partnerID=8YFLogxK
U2 - 10.1038/sj.tpj.6500324
DO - 10.1038/sj.tpj.6500324
M3 - Article
C2 - 16027735
AN - SCOPUS:27144503123
VL - 5
SP - 292
EP - 297
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
SN - 1470-269X
IS - 5
ER -